Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

Publications

Improvement of Severe Fatigue Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

December 8, 2020

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

Read more

Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study

November 16, 2016

Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study

Read more

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus

August 17, 2016

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus

Read more
Load more
Resolve Therapeutics
Resolve Therapeutics, LLC
721 1st Ave. N
St. Petersburg, FL 33701
© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top